


Wisconsin Department of Health Services



Tuberculosis (TB) Screening and Diagnosis

Claire Leback, M^{PH}, RN, BSN
Julie Tans-Kerster, MS, BSMT (ASCP)
Wisconsin Tuberculosis (TB) Program
Northeast TB Summit
November, 2019

1

Wisconsin Department of Health Services


TB Screening and Diagnosis

- Overview of TB in Wisconsin
- Difference between TB and LTBI
- TB Disease
- Latent TB Infection (LTBI)
- LTBI Case Studies

2

Wisconsin Department of Health Services

Tuberculosis Cases, Wisconsin 2009-2018



Year	Cases
2009	65
2010	55
2011	65
2012	65
2013	50
2014	50
2015	65
2016	40
2017	50
2018	49

49 cases of tuberculosis were reported in Wisconsin in 2018

Case average
Wisconsin has had an average of 57 TB cases per year during the past 10 years.

Multi-drug resistance
Wisconsin's rate of multi-drug resistant TB is one of the highest in the U.S. Wisconsin treated 20 patients with MDR-TB in the past 10 years.

Deaths
In 2018, seven people died from TB or complications of the disease.

3

Wisconsin Department of Health Services

DIFFERENCE BETWEEN TB AND LTBI

4

Wisconsin Department of Health Services

LTBI versus TB Disease

Person with LTBI (Infected)	Person with TB Disease (Infectious)
Has a small amount of TB bacteria in his/her body that are alive, but inactive	Has a large amount of active TB bacteria in his/her body
Cannot spread TB bacteria to others	May spread TB bacteria to others
Does not feel sick, but may become sick if the bacteria become active in his/her body	May feel sick and may have symptoms such as a cough, fever, and/or weight loss

5

Wisconsin Department of Health Services

LTBI versus TB Disease

Person with LTBI (Infected)	Person with TB Disease (Infectious)
Usually has a TB skin test or TB blood test reaction indicating TB infection	Usually has a TB skin test or TB blood test reaction indicating TB infection
Radiograph is typically normal	Radiograph may be abnormal
Sputum smears and cultures are negative	Sputum smears and cultures may be positive

6

Wisconsin Department of Health Services	
LTBI versus TB Disease	
Person with LTBI (Infected)	Person with TB Disease (Infectious)
Encourage treatment for LTBI to prevent TB disease	Needs treatment for TB disease
Does not require respiratory isolation	May require respiratory isolation
7	

Wisconsin Department of Health Services	
LTBI versus TB Disease	
Person with LTBI (Infected)	Person with TB Disease (Infectious)
Category II communicable disease	Category I communicable disease
Report within 72 hours to patient's local health department (enter data into WEDSS* or complete case report form).	Immediately report by phone to patient's local health department. Within 24 hours, enter data into WEDSS* or complete case report form.
*WEDSS= Wisconsin Electronic Disease Surveillance System	
8	

Wisconsin Department of Health Services	
TB DISEASE	
9	

Wisconsin Department of Health Services

TB Disease


- Airborne disease caused by the bacterium *Mycobacterium tuberculosis*
- Expelled when a person with infectious TB coughs, sneezes, shouts, or sings
- Transmission occurs when droplet nuclei (airborne particles) are inhaled and reach the alveoli of the lungs, via nasal passages, respiratory tract, and bronchi
- Usually considered a respiratory disease but can affect many other parts of the body.

2018 WI TB Program Update

Wisconsin Department of Health Services

Tuberculosis

- 1.7 billion people infected worldwide (1/4 of the world's population)
- Estimated 10 million new cases of TB disease in 2017
- 1.6 million deaths in 2017
- US: 9,025 TB cases in 2018
- WI: 49 cases in 2018



<http://www.cdc.gov/tb/education/cooccur/index.htm>
http://www.who.int/tb/publications/global_report/en/

2018 WI TB Program Update

Wisconsin Department of Health Services

Wisconsin TB Case Definition

- Communicable Disease Case Reporting and Investigation Protocol
- <https://www.dhs.wisconsin.gov/publications/p01928.pdf>

2018 WI TB Program Update

Wisconsin Department of Health Services

Wisconsin TB Case Definition

- **Suspected:** symptoms and lab tests are consistent with tuberculosis, but diagnostic evaluations are not complete
- **Confirmed:** *M. tuberculosis* complex detected in culture (growth) or by nucleic acid amplification test (NAAT, DNA)
- **Clinical case:** lab results unable to confirm by culture or NAAT, but patient has signs and symptoms consistent with TB, improves on treatment, and has positive tuberculin skin test (TST) or interferon gamma release assay (IGRA) blood test.

2018 WI TB Program Update 13

Wisconsin Department of Health Services

TB Screening and Diagnosis

Risk Assessment: form (F-02314)	Symptom evaluation	Test for TB Infection: tuberculin skin test (TST) or interferon gamma release assay (IGRA) blood test	Chest Imaging: Chest x-ray (CXR) or computed tomography (CT)	Microbiology: AFB smear, culture, nucleic acid amplification testing (NAAT)
---	---------------------------	---	--	---

2018 WI TB Program Update 14

Wisconsin Department of Health Services

TB Screening and Diagnosis

Risk Assessment: form (F-02314) This presentation	Symptom evaluation This presentation Dr. Wisch (extrapulmonary)	Test for TB Infection: tuberculin skin test (TST) or interferon gamma release assay (IGRA) blood test This presentation	Chest Imaging: Chest x-ray (CXR) or computed tomography (CT) Dr. Kanne	Microbiology: AFB smear, culture, nucleic acid amplification testing (NAAT) Laura Louison
--	--	--	---	--

2018 WI TB Program Update 15

Wisconsin Department of Health Services

Wisconsin TB Risk Assessment Questionnaire

<https://www.dhs.wisconsin.gov/tb/index.htm>

WISCONSIN TUBERCULOSIS RISK ASSESSMENT

This tool screening tool to identify asymptomatic adults for latent tuberculosis infection (LTBI) testing. (Do not perform LTBI testing for patients younger than 18 years old.) (Do not perform LTBI testing for patients who are not identified as the screening tool's intended users.)

This tool is for LTBI and active TB disease risk assessment. It is not intended for use in patients who have been diagnosed with TB disease. (Do not use this tool for patients who have been diagnosed with TB disease.)

If one of the following four boxes are checked, recommend LTBI testing. **That for LTBI if LTBI test result is positive and active TB disease is ruled out.**

- Birth, Travel, or Residence in a country with high TB prevalence.**
 - Includes any country other than the United States, Canada, Australia, New Zealand, or a country in possession of nuclear weapons.
 - Includes all countries in Eastern Europe and Central Asia, Afghanistan, Iraq, and all countries with TB prevalence > 1% in a country with TB prevalence.
 - Other a patient over 18 for foreign-born patients 7 years of age or less.
- Close Contact to someone with infectious TB disease during lifetime.**
- Recent TB symptoms.** (Patients cough, bring sputum or more sputum AND one or more of the following symptoms: coughing up blood, night sweats, unexplained weight loss, or fatigue.)
- Current or former antitubercular treatment of a high-risk category setting in a state (other than an identified TB state).**
 - Includes Nurses, Laboratories, Pharmacies, Health Care, New York, Texas, or Washington DC (includes residential facilities, long-term residential care facilities, or shelters) in the territories.
- A TB risk assessment has been completed in the patient's medical record. (No TB infection to TB was identified.)**
- A TB risk assessment has been completed in the patient's medical record. (No TB infection to TB was identified.)** (A TB risk assessment has been completed in the patient's medical record. (No TB infection to TB was identified.)

Name:

Assessment Date:

Age:

Date of Birth:

See the Wisconsin Tuberculosis Risk Assessment Fact Sheet for more information about how to use this tool.

16

Wisconsin Department of Health Services

Wisconsin TB Risk Assessment

- Recently updated to align with national recommendations.
- Includes risk for infection and risk for progression.
- If the patient has any of the risks below, recommend LTBI testing.
- Risks for infection:
 - Birth, travel or residence in a country a high TB rate
 - Close contact to someone with infectious TB disease

2018 WI TB Program Update

17

Wisconsin Department of Health Services

Wisconsin TB Risk Assessment

- Immune suppression alone is not a risk for acquiring TB infection.
- Risk for progression:
 - HIV infection
 - Current or planned immunosuppression (e.g., organ transplant, TNF-alpha antagonist, chronic steroids) in combination with risk for infection from above

2018 WI TB Program Update

18

Wisconsin Department of Health Services

Wisconsin TB Risk Assessment

- Wisconsin has very low incidence of TB in healthcare, homeless, corrections and long-term care settings.
- A recent systematic review found that a low percentage of HCP have a positive TB test at baseline and upon serial testing (MMWR, 2019).
- Higher-risk congregate settings occur in Alaska, California, Florida, Hawaii, New Jersey, New York, Texas or Washington DC

2018 WI TB Program Update 19

Wisconsin Department of Health Services

Wisconsin Populations at Risk for TB

- Immigrants and refugees from TB high-burden countries
- Lao-Hmong born outside the US
- Students and tech workers born in TB high-burden countries
- Hispanic or Latino migrant farm or livestock workers
- African American individuals in Southeast Wisconsin in the Milwaukee-Chicago corridor

20

Wisconsin Department of Health Services

TB Signs and Symptoms

- Cough for more than three weeks with sputum production, bloody sputum
- Unexplained fever or fatigue for more than three weeks, chills
- Drenching night sweats
- Unexplained weight loss of more than ten pounds
- Enlarged lymph node
- Pain (in joint)
- Confusion (meningitis)

2018 WI TB Program Update 21

Wisconsin Department of Health Services



INTERFERON GAMMA RELEASE ASSAYS (IGRAs)

2018 WI TB Program Update 22

Wisconsin Department of Health Services

Interferon Gamma Release Assays (IGRAs)

- Detect the presence of *M. tuberculosis* infection by measuring the immune response to TB proteins (antigens) in whole blood.
- Cannot differentiate between LTBI and active TB disease. Additional tests are needed to diagnose or rule out TB disease.
- Can be used in all situations in which CDC recommends tuberculin skin test (TST) as an aid in diagnosing *M. tuberculosis* infection.

2018 WI TB Program Update 23

Wisconsin Department of Health Services

Interferon Gamma Release Assays (IGRAs)

Two IGRAs are commercially available and approved by the U.S. Food and Drug Administration (FDA) as aids in diagnosing *M. tuberculosis* infection:

- QuantiFERON®-TB Gold In-Tube test (Qiagen)
- T-SPOT®.TB test (Oxford Immunotec)

2018 WI TB Program Update 24

Wisconsin Department of Health Services

How IGRAs Work

- A whole blood sample is collected from the patient.
- During the assay:
 - Blood cells are exposed to TB-specific antigens (ESAT-5, CFP-10, TB7.7).
 - Interferon gamma is released from patient's activated white blood cells (T-cells) and measured.
- The amount of interferon gamma detected indicates whether the patient has been exposed to *M. tuberculosis* complex.

2018 WI TB Program Update 25

Wisconsin Department of Health Services

IGRA Results

Result	Description	Acceptable Value (IU/mL)	Significance
Mitogen	Positive Control	≥ 0.5 ≥ 20 spots	Addresses the immune competence of the patient's immune cells. A low mitogen result indicates inability to respond to an antigen.
Nil	Negative Control	≤ 8.0 ≤ 10 spots	Indicates the presence of any residual gamma interferon found in the patient's blood due to an ongoing immune response (infection) that can cause a false-positive result.
Patient Result	TB Antigen Minus Nil	See next slide	Quantitation of interferon gamma: Indicates patient's response to TB antigens.

2018 WI TB Program Update 26

Wisconsin Department of Health Services


IGRA Results

IGRA Test Result	QuantiferON	T-SPOT	Notes
Positive	≥ 0.35	≥ 8 spots	Infection is likely
Negative	< 0.35	≤ 4 spots	Infection unlikely
Indeterminate or invalid	High nil value or low mitogen value	High nil value or low mitogen value	Not clinically interpretable. Occurs if controls do not perform as expected. Collect another specimen for retesting.
Borderline (equivocal)	Not applicable	5, 6 or 7 spots	Uncertain likelihood of TB infection. Collect another specimen for retesting.

2018 WI TB Program Update 27

Wisconsin Department of Health Services


Tuberculin Skin Test (TST)



2018 WI TB Program Update

Wisconsin Department of Health Services

Tuberculin Skin Testing (TST)



- Five Tuberculin Units (TU) of Purified Protein Derivative (PPD)
- Read at 48-72 hours
- False positives include:
 - Non-Tuberculosis Mycobacteria (NTM)
 - Recent Bacillus Calmette-Guérin (BCG) vaccination
- Interpretation depends on person's risk factors

2018 WI TB Program Update

Wisconsin Department of Health Services

TST Interpretation Reaction in Millimeters

≥ 5 mm induration is considered positive for:

- Persons infected with HIV*
- Recent contact of a person with infectious TB disease
- Persons with fibrotic changes on chest radiograph consistent with prior TB; and
- Patient with organ transplants and other immunosuppressed patients (including patients receiving the equivalent of ≥15mg/day of prednisone for ≥ 1 month or those taking TNF- α ^o antagonists.

* Human immunodeficiency virus. ^oTumor Necrosis Factor -alpha inhibitor

2018 WI TB Program Update

Wisconsin Department of Health Services

TST Interpretation Reaction in Millimeters

≥ 10 mm induration is considered positive for:

- Recent arrivals from high-prevalence countries
- Injection drug users
- Health care workers
- Residents and employees of high-risk congregate settings
- Mycobacteriology laboratory personnel
- Children < 4-years-old or child and youth exposed to adults at high-risk
- Persons with conditions that increase risk for progressing to TB disease including: silicosis, diabetes mellitus, chronic renal failure, certain types of cancer, gastrectomy or jejunioileal bypass and weight loss of at least 10% below ideal body weight

2018 WI TB Program Update 31

Wisconsin Department of Health Services

TST Interpretation Reaction in Millimeters

≥ 15 mm induration is considered positive for:

- Persons with no known risk factor for TB disease
- Although TST testing programs should be conducted only among high-risk groups, certain individuals may required testing for employment or school attendance. An approach independent of risk assessment is not recommended by the Centers of Disease Control and Prevention (CDC).

2018 WI TB Program Update 32

Wisconsin Department of Health Services

Chest Imaging

- Chest radiographs (x-ray or CT) are performed when there is a positive TST, IGRA or symptom screening evaluation.
- Findings suggestive of TB disease:
 - Nodules, opacities, granulomas, millets, infiltrate
 - Cavitation
 - "Tree in bud" patterns
 - Pleural effusion or thickening
 - Enlarged lymph nodes
- These findings often warrant sputum collection.

2018 WI TB Program Update 33

Wisconsin Department of Health Services

Indications for Sputum Collection

- Initial diagnosis of TB: Collect a series of three sputum specimens, 8-24 hours apart, at least one of which is an early morning specimen.
- Optimally, diagnostic sputum should be collected before the initiation of drug therapy.
- Monitoring of therapy: Obtain sputum specimens for culture at least monthly until cultures convert to negative.

Centers for Disease Control and Prevention. Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Settings. MMWR 2005;54, RR-17

2018 WI TB Program Update 54

Wisconsin Department of Health Services

Methods of Diagnosis: Microbiology

Method	Sensitivity for TB	What positive result looks like	Interpretation
Smear (view bacteria by microscope)	Poor	AFB smear positive # organisms per field Few/moderate/many	Does not confirm tuberculosis
Culture (growth of bacteria)	Very good	Isolated: <i>M. tuberculosis</i> complex	Confirms tuberculosis disease
PCR (detection of DNA)	Good	" <i>M. tuberculosis</i> complex DNA detected"	Confirms tuberculosis disease

2018 WI TB Program Update 35

Wisconsin Department of Health Services

Case Study #1

- 45 year old male, born in U.S.
- Respiratory symptoms for several weeks
- QuantiFERON® negative
- Abnormal CXR
- Five sputum smears are all negative
- Work with foreign-born individuals through his job as a salesperson

2018 WI TB Program Update 36


Wisconsin Department of Health Services

Case Study #2

- 75 year old woman from Laos
- Respiratory symptoms on and off for several months
- Diagnosed with asthma, allergies, COPD, pneumonia
- QuantiFERON® negative
- Abnormal CXR

2018 WI TB Program Update 37

Wisconsin Department of Health Services



LATENT TUBERCULOSIS (TB) INFECTION

Claire Leback, RN, MPH
Tuberculosis Nurse Consultant
Wisconsin Tuberculosis Program
Nov 6th, 2019

38

Wisconsin Department of Health Services


LTBI OVERVIEW

- Review key features
- Case definitions and reporting
- Employee screening & testing
- Testing interpretation
- Case studies


39

Wisconsin Department of Health Services

Review: Latent Tuberculosis Infection (LTBI) is different than active TB disease



Only a small % progress to active disease



■ Become Active
5-10%

40

Wisconsin Department of Health Services

LTBI Reporting and Investigation Protocol

<https://www.dhs.wisconsin.gov/publications/p02303.pdf>

Report LTBI within 72 hours to the local health department.

41

Wisconsin Department of Health Services

Case Definition for LTBI: Laboratory Criteria

- Immunologic:
 - Positive interferon gamma release assay (IGRA) blood test or
 - Positive tuberculin skin test (TST)
- Microbiologic:
 - Culture negative for *M. tuberculosis* complex (if specimen collected)

42

Wisconsin Department of Health Services

Case Definition for LTBI: Clinical Criteria

- No signs or symptoms consistent with TB disease
AND
- Chest imaging without abnormalities consistent with TB disease
- If chest imaging is abnormal and could be consistent with TB disease, then TB disease must be clinically ruled out.

43

Wisconsin Department of Health Services

Case Definition for LTBI

- **Suspected:** A case that meets the laboratory (immunologic and microbiologic) criteria, but lacks sufficient clinical information
- **Confirmed:** A case that meets clinical **AND** laboratory (immunologic and microbiologic) criteria
- Both suspected and confirmed LTBI are reportable.


44

Wisconsin Department of Health Services

Reporting and Documenting LTBI

For reporting:

- **Form F-02265 (LTBI Confidential Case Report)**
- Form F-44151 (Acute and Communicable Disease Case Report)



For documentation of follow-up:

- **Form F-44125 (LTBI Follow-Up Report)**


<https://www.dhs.wisconsin.gov/tb/forms.htm>

45

Wisconsin Department of Health Services

LTBI Confidential Case Report Form F-02265 (preferred)


46



Wisconsin Department of Health Services

LTBI Follow-Up Report Form F-44125

47



Wisconsin Department of Health Services

Knowledge Check

True/False: LTBI is reportable to the local health department within 24 hours.

False! LTBI is reportable within 72 hours. Active TB cases must be reported immediately.

48

Wisconsin Department of Health Services

TB SCREENING FOR SPECIAL POPULATIONS

49

Wisconsin Department of Health Services

TB screening in healthcare settings is regulated by Wisconsin statutes and administrative codes.

- Requirements for screening upon hire for healthcare personnel (HCP) and caregivers
- Screening: TB risk assessment, symptom evaluation, TB testing

Administrative Code	Facility Type
DHS 124 (not enforceable)	Hospital
DHS 132	Nursing Home
DHS 133	Home Health Agency
DHS 83	Community Based Residential Facility

50

Wisconsin Department of Health Services

New Guidance for TB: Screening and Testing of HCP

Morbidity and Mortality Weekly Report

Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019

Jayna E. Sosa, MD^{1,2}; Chaeil J. Noh, MPH³; Mark N. Lubiano, MD⁴; Sagun Baruah; Morris, MD⁵; William Buckles, MD^{6,7}; Megan L. Casey, MPH⁸; Neela D. Gowans, MD⁹; Marylène Gendron, MN¹⁰; Bobby Jo Hume¹¹; Anura R. Khan, MPH¹²; David T. Kohler, MD¹³; David M. Lewinschun, MD, PhD¹⁴; Tim A. Mathers, MD¹⁵; Gerald H. Muench, MD¹⁶; Randall Revo, MD^{17,18}; Lisa Pankin, MPH^{19,20}; Wendy Thomas, MD^{21,22}; Lorenz Will, MA²³; Robert Willingham, MD²⁴

51

Wisconsin Department of Health Services

New MMWR 2019 Guidance: TB Screening and Testing of HCP

Testing	Old guidelines	New guidelines
Baseline IGRA or two-step TST	Yes, for all HCP, regardless of risk	Yes, for all HCP, regardless of risk
Serial (annual) testing using IGRA or TST	Based on risk classification of facility	Not recommended
IGRA or TST for HCP upon unprotected exposure to <i>M. tuberculosis</i>	Perform a contact investigation (i.e. administer one test as soon as possible at the time of exposure, and if result is negative, perform another test 8-10 weeks after the end of exposure to <i>M. tuberculosis</i>).	

IGRA, interferon gamma release assay; TST, tuberculin skin test

52

Wisconsin Department of Health Services

New MMWR 2019 Guidance: TB Screening and Testing of HCP

Annual testing:

- A systematic review found a low percentage of U.S. HCP have a positive TB test at baseline and upon serial testing.
- No routine serial TB testing is recommended at any interval after baseline in the absence of a known exposure or ongoing transmission.

53

Wisconsin Department of Health Services

New MMWR 2019 Guidance: TB Screening and Testing of HCP

- Encourage treatment for all health care personnel with untreated LTBI, unless treatment is contraindicated
- Annual symptom screening for health care personnel with untreated LTBI
- Annual TB education of all health care personnel
 - TB risk factors
 - Signs and symptoms of TB disease
 - TB infection and control policies and procedures

54

Wisconsin Department of Health Services

What does HCP screening look like?

Screening and Testing New HCP:

- HCP should be tested upon hire using IGRA (preferred) or tuberculin skin test, include TB risk assessment, and symptom evaluation.
- Baseline screening and testing can:
 - Serve as a baseline should an exposure occur and a TB contact investigation be necessary
 - Facilitate detection and treatment of LTBI or TB disease in HCP before employment begins.
 - Risk assessment used to interpret test results

55

Wisconsin Department of Health Services

What does HCP screening look like?

Screening New HCP:

- Baseline screening should be performed before assumption of duties in which HCP will have contact with patients.
- If TST is used as the baseline testing, 2-step testing is recommended for HCP who do not have a documented TST result during the previous 12 months or fewer than 2 TSTs over lifetime.¹

56

Wisconsin Department of Health Services

What does HCP screening look like?

Screening and Testing New HCP:

- At the discretion of the facility, previous documented negative IGRA or TST results may be used for employment.
 - A new baseline TB risk assessment and symptom evaluation should be performed.

57

Wisconsin Department of Health Services

What does HCP screening look like after baseline?

Annual screening of HCP:

- Instead of annual testing, facilities can consider annual individual TB risk assessments.
 - Recognizes non-occupational exposures to TB.
- HCP should be educated on TB risk factors for infection and progression, the signs and symptoms of TB disease, and TB infection control policies.
- HCP with history of LTBI or previous positives should have symptom evaluation annually.

58

Wisconsin Department of Health Services

TB Screening and Testing in Healthcare Personnel

Tuberculosis Screening and Testing: Health Care Personnel

Definitions:
Medical Evaluation: Assessment of signs and symptoms of active tuberculosis (TB) disease.
Risk Assessment: Use of a questionnaire to determine a person's risk for TB infection.
Testing: Performance of diagnostic gamma interferon (IGRA) blood test or tuberculin skin test (TST) to determine if a person has been infected with *M. tuberculosis* complex bacteria.

Recommendations for Screening and Testing Update Note

Screening for TB infection and disease is recommended for health care personnel (HCP) upon hire and includes the following components: risk assessment, testing, and medical evaluation, if indicated.


- A baseline TB risk assessment questionnaire should be performed for HCP to determine risk for TB infection. See resources for an example questionnaire.
- For testing, an IGRA or TST may be performed (IGRA is preferred). See Figure 3 on page 2 for interpretation of testing results.
- If testing is positive, notify staff in real time and refer HCP to provider for medical evaluation.
- In the absence of the testing, medical evaluation (IGRA or TST) should be used. However, a new baseline TB risk questionnaire is required and medical evaluation, if indicated, should be performed.
 - If TST is used for baseline testing, a 2nd testing is recommended for HCP who have not had TST testing previously or have any but one negative TST test greater than 12 months ago.
- Initial risk assessment, testing, and medical evaluation can serve as a baseline check on exposure and a TB control investigation tool. Subsequently, baseline risk assessment, testing, and medical evaluation can facilitate the detection and treatment of latent tuberculosis infection (LTBI) and TB disease in HCP, thereby reducing the risk and reducing the risk of transmission to patients and other HCP.
- Screening should be performed before recruitment of staff in which HCP will have direct contact with patients.
- HCP should be educated on the signs and symptoms of TB disease and risk for disease progression, and should seek medical evaluation if disease occurs.

Most Wisconsin healthcare facilities are considered low risk for TB, annual (annual) testing by IGRA or TST is not recommended.

59

Wisconsin Department of Health Services

Screening in Wisconsin Schools



60

Wisconsin Department of Health Services

Screening and testing in schools is regulated by WI DHS 118.25 and DHS 125

- School employees who are in contact with children or prepare food are required to have a physical examination, symptom evaluation, and TB risk assessment at hire.
 - TB testing needed if indicated by risk assessment.
- School bus drivers are required to have symptom evaluation, risk assessment, and testing at hire.

61

Wisconsin Department of Health Services


WTBP Website>Forms

- Record for school employees, F-02284
- Risk Assessment for Public School Employees, F-02314A

62

Wisconsin Department of Health Services

Screening in Corrections



63

Wisconsin Department of Health Services

Screening in corrections is based on CDC recommendation and facility policy

- All facilities should screen all detainees for active TB disease.
 - Symptom evaluation, but can be chest radiograph, especially for certain high risk populations (e.g., HIV+).
- Some facilities should also test for TB infection.
 - Those that house a "substantial" number of detainees with risk factors or house long-term inmates (>1 year).
 - Test long-term inmates annually.
- All workers should have baseline and annual risk assessment, symptom evaluation, and testing if indicated.

64

Wisconsin Department of Health Services

Knowledge Check

True/False: Healthcare personnel and caregivers should undergo annual testing.


False! It is not recommended that healthcare personnel and caregivers receive repeated/serial testing in the absence of known exposure or evidence of transmission.

65

Wisconsin Department of Health Services

**YOU'VE SCREENED & TESTED...
NOW WHAT?**

66



Wisconsin Department of Health Services

Interpretation of results for low-risk individuals

- Guidelines recommend confirmatory or dual testing for individuals unlikely to be infected. ⁴
- Individuals unlikely to be infected and at low risk for progression should have a second test (IGRA or TST) performed.
- Low-risk individuals should be considered infected with *M. tuberculosis* only if both the first and second tests are positive. ⁴

68

Wisconsin Department of Health Services

Additional Tip: Look at IGRA numeric results to help evaluate low-risk patients

- Especially for patients with little or no risk for *M. tuberculosis* infection, numeric IGRA results are helpful to determine likelihood of infection.
- TB antigen values between 0.36 and 1.11 IU/mL were found to represent a "borderline" range. ²⁻⁸
 - Results in this range may be considered a transient positive result with a high likelihood of reversion to negative upon retesting.

69

Wisconsin Department of Health Services

TST-Induced IGRA Response Boosting: What does it mean?

- If an IGRA is performed three or more days after a TST, the numeric results might increase.
- This is because the TST causes an immune response within the patients' body which can subsequently be detected by IGRA testing.
- In studies, boosting occurred in both T-SPOT®TB and QFT-GIT® assays.
- Boosting occurred predominantly in IGRA-positive subjects, however a significant percentage (12.5%) also occurred in IGRA-negative subjects.⁹

70

Wisconsin Department of Health Services

IGRA Positive: What's Next?

Positive Interferon Gamma Release Assay (IGRA) - What's Next?

The Wisconsin Tuberculosis Program (WTP) recommends an interferon gamma release assay (IGRA) rather than a tuberculin skin test (TST) for individuals 2 years of age or older. Your physician or nurse may or may not have a question or concern about being boosted for a positive TST or IGRA result. The guidance in this document will help you understand the question. Your local health department (LHD) can assist with this situation.

Does my patient have any of these risk factors?

Groups with increased likelihood of infection with TB

- Birth, travel (including education), or residence in a country with high TB prevalence.
- Close contact with someone with infectious TB disease.
- Recent TB (contingent upon treatment success) from three weeks and one or more of the following symptoms: coughing, chest pain, night sweats, unexplained weight loss, or fatigue.
- Contact or "household exposure" to someone with a high-risk mycobacterium (e.g. multidrug-resistant, long-term resistant) infectious agent. TB. This includes close contacts with an identified TB case (Illinois, California, Florida, Hawaii, New Jersey, New York, Texas, or Washington DC).

<p>Do they have two or more of the following symptoms? cough, chest pain, night sweats, unexplained weight loss, or fatigue</p> <p>YES / NO</p>		<p>Does my patient have any of the following symptoms? coughing, chest pain, night sweats, unexplained weight loss, or fatigue</p> <p>YES / NO</p>	
<p>YES ✓</p> <p>Patients should have a physician evaluate for active TB disease.</p> <p>If the patient is not infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is not infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is not infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is infectious, the patient has TB and should have a physician evaluate for active TB disease.</p>	<p>NO</p> <p>Patients should have a physician evaluate for active TB disease.</p> <p>If the patient is not infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is not infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is infectious, the patient has TB and should have a physician evaluate for active TB disease.</p>	<p>YES ✓</p> <p>Patients should have a physician evaluate for active TB disease.</p> <p>If the patient is not infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is not infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is infectious, the patient has TB and should have a physician evaluate for active TB disease.</p>	<p>NO</p> <p>Patients should have a physician evaluate for active TB disease.</p> <p>If the patient is not infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is not infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is infectious, the patient has TB and should have a physician evaluate for active TB disease.</p>

71

Wisconsin Department of Health Services

TST Positive: What's Next?

Positive Tuberculin Skin Test (TST) - What's Next?

The Wisconsin Tuberculosis Program (WTP) recommends an interferon gamma release assay (IGRA) rather than a tuberculin skin test (TST) for individuals 2 years of age or older. If TST is performed in health care settings, it is a value of the tuberculin skin test (TST) is less than 5 mm or 10 mm, it is considered a negative result. A TST of 5 mm or more but less than 10 mm is considered a "borderline" result. A TST of 10 mm or more is considered a positive result. Your local health department (LHD) can assist with this situation.

Does my patient have any of these risk factors?

Groups with increased likelihood of infection with TB

- Birth, travel (including education), or residence in a country with high TB prevalence.
- Close contact with someone with infectious TB disease.
- Recent TB (contingent upon treatment success) from three weeks and one or more of the following symptoms: coughing, chest pain, night sweats, unexplained weight loss, or fatigue.
- Contact or "household exposure" to someone with a high-risk mycobacterium (e.g. multidrug-resistant, long-term resistant) infectious agent. TB. This includes close contacts with an identified TB case (Illinois, California, Florida, Hawaii, New Jersey, New York, Texas, or Washington DC).

<p>Do they have two or more of the following symptoms? cough, chest pain, night sweats, unexplained weight loss, or fatigue</p> <p>YES / NO</p>		<p>Does my patient have any of the following symptoms? coughing, chest pain, night sweats, unexplained weight loss, or fatigue</p> <p>YES / NO</p>	
<p>YES ✓</p> <p>Patients should have a physician evaluate for active TB disease.</p> <p>If the patient is not infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is not infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is infectious, the patient has TB and should have a physician evaluate for active TB disease.</p>	<p>NO</p> <p>Patients should have a physician evaluate for active TB disease.</p> <p>If the patient is not infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is not infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is infectious, the patient has TB and should have a physician evaluate for active TB disease.</p>	<p>YES ✓</p> <p>Patients should have a physician evaluate for active TB disease.</p> <p>If the patient is not infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is not infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is infectious, the patient has TB and should have a physician evaluate for active TB disease.</p>	<p>NO</p> <p>Patients should have a physician evaluate for active TB disease.</p> <p>If the patient is not infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is not infectious, the patient has TB and should have a physician evaluate for active TB disease.</p> <p>If the patient is infectious, the patient has TB and should have a physician evaluate for active TB disease.</p>

72

Wisconsin Department of Health Services

LTBI CASE STUDIES

73

Wisconsin Department of Health Services

Case study 1

55 y.o. Caucasian woman undergoes pre-employment testing by TST. Her result is 16mm. No symptoms. CXR is negative. No reported exposure, born in the U.S.

- What would you classify her risk as?
- What would you anticipate for next steps?

74

Wisconsin Department of Health Services

Case Study 1

What would you classify her risk as?

- A. Low risk
- B. High risk

What would you anticipate for next steps?

- A. Order LTBI medications
- B. Perform second, confirmatory test
- C. Collect sputum

75

Wisconsin Department of Health Services

Case study 2

29 y.o. Asian male undergoes testing by QFT for his graduate school program. Results are as follows
nil=0.05, Tb1-nil=0.76, Tb2-nil=0.56, Mit=>10.0. No symptoms. CXR is negative. No reported exposure, born in China.

- What would you classify his risk as?
- What would you anticipate for next steps?

76

Wisconsin Department of Health Services

Case study 2

What would you classify his risk as?

- A. Low risk
- B. High risk








What would you anticipate for next steps?

- A. Order LTBI medications
- B. Perform a second test
- C. Collect sputum

77

Wisconsin Department of Health Services

TB Program Staff

 Julie Tans-Kersten	 Pat Heger	 Taylor LaBorde	
 Claire Leback	 Kent Mok	 Savitri Tsering	 Philip Wegner

78

Wisconsin Department of Health Services

TB Program Contact Information


Phone: 608-261-6319
 Fax: 608-266-0049
 Email: DHSWITBProgram@dhs.wisconsin.gov

Website:
<https://www.dhs.wisconsin.gov/tb/index.htm>

79

Wisconsin Department of Health Services

Questions?



80

Wisconsin Department of Health Services

References

1. P. Jensen, L. Lambert, V. Iademarco, R. Ridzon, Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention. "Guidelines for preventing the transmission of mycobacterium tuberculosis in health-care settings, 2005." *MMWR*, vol. 54, RR 17, pp1-141, 2005.
2. R. Beknap, J. Kelaher, K. Wall et al., "Diagnosis of latent tuberculosis infection in U.S. health care workers: reproducibility, repeatability and 6-month follow-up with interferon-γ release assays (IGRAs)," *American Journal of Respiratory and Critical Care Medicine*, vol. 179, Article ID A4101, 2009.
3. J. T. Costa, R. Silva, R. J. A. M. J. Cardoso, and A. Nienhaus, "Serial testing with the interferon-γ release assay in Portuguese healthcare workers," *International Archives of Occupational and Environmental Health*, vol. 84, no. 4, pp. 461-469, 2011.
4. K. S. Fong, J. W. Tomford, L. Teixeira et al., "Challenges of interferon-γ release assay conversions in serial testing of health care workers in a tuberculosis control program," *Chest*, vol. 142, no. 1, pp. 55-62, 2012.
5. D. Lewinsohn et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. *Clin Infect Dis* 2017, 64 (2): 111-115.
6. M. Pai, R. Joshi, S. Dajra et al., "Serial testing of health care workers for tuberculosis using interferon-γ assay," *American Journal of Respiratory and Critical Care Medicine*, vol. 174, no. 3, pp. 349-355, 2006.
7. A. Schablon, M. Harling, R. Diehl et al., "Serial testing with an interferon-γ release assay in German healthcare workers," *GMS Krankheitshygiene Interdisziplinär*, vol. 5, no. 2, Article ID Doc05, 2010.
8. W. Thanassi, A. Noda, B. Hernandez, J. Newell, P. Terpeluk, D. Marder, JA Yesavage. Delineating a retesting zone using receiver operating characteristic analysis on serial QuantiFERON tuberculosis test results in US healthcare workers. *Pulm Med* 2012;2012:291294.
9. R. Van Zyl-Smit, M. Pa, K. Pappiah, R. Meisbau, J. Kieck, J. Juritz, M. Bardi, A. Zumla, L. Sechi, E. Bateman, K. Dheda. Within-subject variability and boosting of T-cell interferon-γ responses after tuberculin skin testing. *American Journal of Respiratory and Critical Care Medicine*, vol. 180, pp. 49-58, 2009.

81
